Oncology Information Systems Market is expected to surpass US$ 5.48 Billion by 2032 | FMI

 The Oncology Information Systems Market is predicted to be worth US$ 2.59 billion by 2022 and to rise to US$ 5.4 billion by 2032, at a 7.8% CAGR from 2022 to 2032. 



The increasing incidence and prevalence of cancer, as well as the growing need to reduce the cost of cancer care, are driving the oncology information system market growth, as are the potential benefits offered by oncology information systems in cancer treatment, management, and planning.

Get More Information on this Report @ https://www.futuremarketinsights.com/reports/oncology-information-systems-market

The oncology information system market includes software and services used for comprehensive information and image management, which aids in the management and optimization of cancer patient profiles and treatment.

The rising incidence of cancer cases is one of the major factors driving the oncology information system market growth. There are a few other factors driving the oncology information system market key trends and opportunities, such as the growing need to reduce oncology care costs and the growing adoption of oncology information system along with electronic health records (EHR) and other oncology information systems.

A major impediment to implementing OIS solutions in hospitals is a lack of qualified resources influencing the oncology information system market future trends along with oncology information system market opportunities. Currently, the demand for healthcare IT professionals outnumbers supply in both developing and developed oncology information system market, including the United States and Europe.

Asia Pacific accounted for 17.8% of the oncology information system market. The Asia Pacific oncology information system market is expanding due to several factors, including rising cancer prevalence and increased investment in the implementation of IT solutions in healthcare settings which h influences the oncology information system market adoption trends.

KEY TAKEAWAYS:

  • The oncology information system market has been divided into two segments: solutions and professional services. The solutions segment accounted for the majority of revenue i.e. 73.4%.
  • The solutions segment is further subdivided into patient information systems and treatment planning systems, with the latter accounting for the lion's oncology information system market share.
  • Medical oncology accounted for the largest oncology information system market share of global revenue, accounting for 61.4% of total revenue.
  • In 2021, the North America regional oncology information system market had the highest oncology information system market share's revenue of 38.5%.
  • The software segment accounted for 83.6% of the product and service oncology information system market.
  • Radiation oncology accounted for 53.8% of the oncology information system market.
  • Asia Pacific accounted for 17.8% of the oncology information system market.

COMPETITIVE LANDSCAPE:

Key oncology information system market companies are primarily focused on incorporating technological innovation with the introduction of web-based oncology solutions and AI-based oncology information system solutions with the goal of improving the treatment regime, which is expected to positively impact oncology information system market growth in the near future.

Elekta AB, Accuray Inc., Varian Medical Systems, RaySearch Laboratories, Cerner Corp., BrainLab, Philips Healthcare, Prowess, Inc., DOSIsoft S.A., ViewRay Inc., MIM Software, and Flatiron are among the prominent players in the oncology information system market.

RECENT DEVELOPMENT:           

  • Varian Medical Systems, Inc. announced a USD 10.0 million investment and a strategic collaboration agreement with COTA, Inc., a curator of clinical data in the oncology sector, in 2020.
  • Siemens Healthineers (Germany) completed the acquisition of Varian Medical System in August 2021. (UK). The goal of this acquisition was to create a one-of-a-kind, highly integrated portfolio of oncology information system workflow.
  • Koninklijke Philips N.V. (The Netherlands) and Elekta (Sweden) will collaborate in June 2021 to develop advanced, comprehensive, and personalised cancer care through precision oncology information solutions.
  • McKesson Corporation (US) has launched Ontada, an oncology technology and insights business dedicated to advancing cancer research and care, in December 2020.

Key Segments 

By Product:

  • Solutions
    • Patient Information Systems
    • Treatment Planning Systems
  • Professional Services

By Application:

  • Medical Oncology
  • Radiation Oncology
  • Surgical Oncology

By Region:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • UAE

Comments

Post a Comment

Popular posts from this blog

Pet Diabetes Care Devices Market Report | Size, Growth, Demand, Scope and Forecast to 2032

  The global  Pet Diabetes Care Devices Market  is expected to grow at a  6.5%  CAGR, reaching  US$ 4 billion  by 2032, up from  US$ 2 billion  in 2021. “The number of pets with diabetes, the number of adopted pets, and the number of overweight pets are all driving the market forward.” Get Full Access @ https://www.futuremarketinsights.com/reports/pet-diabetes-care-devices-market The domestication of animals is leading to a lack of insulin production in them. The limited flow of glucose to the cell can be termed diabetes. This chronic disease is a major concern for pet owners and needs to be taken care of. This concern leads to the expansion of the pet diabetes care devices market. Devices like the alphatrak blood glucose meter are in use as they help the pet owners monitor the pet’s health. The increased number of people adopting pets and then domesticating them around in their households, treating and caring for them as f...
Read more

Human Immunodeficiency Virus Type 1 (HIV 1) Market Opportunity, Competitive Analysis, Future Prospects to 2033

Image
  The global Human Immunodeficiency Virus Type 1 (HIV 1) Market is predicted to exceed a remarkable valuation of US$ 34.83 Billion in 2023, with a compound annual rate of growth (CAGR) of 6% estimated from 2023 to 2033. The Institute for Health Metrics and Evaluation attributes the industry's growth to the soaring incidence rate of HIV-1 infection, which, unlike the deaths caused from this viral illness, has not updated substantially over time. Get Full Access @ https://www.futuremarketinsights.com/reports/human-immunodeficiency-virus-type-1-hiv1-market It affected approximately 37 million people worldwide. Furthermore, antiretroviral therapeutic interventions for disease management are only available to half of this population. HIV-1 is the more common of the two types of human immunodeficiency virus, accounting for approximately 96% of all infections globally. The prevalence of HIV is rising at an alarming rate. The World Health Organization (WHO) estimates that 33.0 million...
Read more

Clostridium Diagnostics Market in US is anticipated to secure a market value worth US$ 2.7 Billion by 2032 | FMI

Image
  The global Clostridium Diagnostics Market is expected to grow at a CAGR of 12.2% during the forecast period, from US$ 2.5 billion in 2022 to US$ 7.8 billion by 2032. The market grew at a CAGR of 13.6% between 2015 and 2021. The rising prevalence of clostridium-related diseases, as well as increased campaigns to educate people about the condition, are driving the market growth. To learn more about this report @ https://www.futuremarketinsights.com/reports/clostridium-diagnostics-market here has been an increased focus of players in the market to offer vaccines, which can augment the market size in the forecast period. For instance, in March 2022, Japan launched a new center, with a budget of US$ 1.6 Billion, to support vaccine and drug projects as a part of a larger scheme to tackle infectious diseases. SCARDA will be in charge of establishing a flagship R&D site for innovative collaborations and controlling funds for R&D projects. Awareness camp...
Read more